Quercetin prevents experimental glucocorticoid-induced osteoporosis: A comparative study with alendronate

Canadian Journal of Physiology and Pharmacology

Volumn 91, Issue 5, 2013, Pages 380-385

  Derakhshanian, Hoda ^a   Djalali, Mahmoud ^a   Djazayery, Abolghassem ^a   Nourijelyani, Keramat ^a   Ghadbeigi, Sajad ^a   Pishva, Hamideh ^a   Saedisomeolia, Ahmad ^a   Bahremand, Arash ^b   Dehpour, Ahmad Reza ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alendronate; Glucocorticoid; Osteoporosis; Quercetin; Rat

Indexed keywords

ALENDRONIC ACID; CALCIUM; METHYLPREDNISOLONE SODIUM SUCCINATE; OSTEOCALCIN; PHOSPHORUS; QUERCETIN;

ANIMAL EXPERIMENT; ARTICLE; BODY MASS; BONE STRENGTH; BONE TURNOVER; CALCIUM BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; RAT;

ALENDRONATE; ANIMALS; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY CONSERVATION AGENTS; DISEASE MODELS, ANIMAL; FEMALE; FEMUR; GLUCOCORTICOIDS; METHYLPREDNISOLONE HEMISUCCINATE; OSTEOGENESIS; OSTEOPOROSIS; PILOT PROJECTS; QUERCETIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84877316634     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2012-0190     Document Type: Article

References (33)

1. Canalis, E., Mazziotti, G., Giustina, A., and Bilezikian, J. 2007. Glucocorticoidinduced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18(10): 1319-1328. doi:10.1007/s00198-007-0394-0. PMID:17566815.
2. Cassidy, A. 2003. Potential risks and benefits of phytoestrogen-rich diets. Int. J. Vitam. Nutr. Res. 73(2): 120-126. doi:10.1024/0300-9831.73.2.120. PMID: 12747219.
3. Chen, Y.M., Ho, S.C., Lam, S.S.H., Ho, S.S.S., and Woo, J.L.F. 2003. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: A double-blind, randomized, controlled trial. J. Clin. Endocrinol. Metab. 88(10): 4740-4747. doi:10.1210/jc.2003-030290. PMID:14557449.
4. Chen, X., Yin, O.Q.P., Zuo, Z., and Chow, M.S.S. 2005. Pharmacokinetics and modeling of quercetin and metabolites. Pharm Res. 22(6): 892-901. doi:10. 1007/s11095-005-4584-1. PMID:15948033.
5. Cruse, L.M., Valeriano, J., Vasey, F.B., and Carter, J.D. 2006. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J. Clin. Rheumatol. 12(5): 221-225. doi:10.1097/01.rhu.0000242778.65766.22. PMID:17023807.
6. Dallman, M.F., Akana, S.F., Pecoraro, N.C., Warne, J.P., la Fleur, S.E., and Foster, M.T. 2007. Glucocorticoids, the etiology of obesity and the metabolic syndrome. Curr. Alzheimer Res. 4(2): 199-204. doi:10.2174/156720507780362236.PMID:17430247.
7. Diel, I.J., Bergner, R., and Grotz, K. 2007. Adverse effects of bisphosphonates: current issues. J. Support. Oncol. 5(10): 475-482. PMID:18240669.
8. Eason, J.M., Dodd, S.L., Powers, S.K., and Martin, A.D. 2000. Detrimental effects of short-term glucocorticoid use on the rat diaphragm. Phys. Ther. 80(2):160-167. PMID:10654062.
9. Fujita, T., Satomura, A., Hidaka, M., Ohsawa, I., Endo, M., and Ohi, H. 2000. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy. Calcif. Tissue Int. 66(3): 195-199. doi:10.1007/s002230010039. PMID:10666494.
10. Iwamoto, J., Seki, A., Takeda, T., Sato, Y., Yamada, H., Shen, C.L., et al. 2006. Preventive effects of risedronate and calcitriol on cancellous osteopenia in rats treated with high-dose glucocorticoid. Exp. Anim. 55(4): 349-355. doi:10. 1538/expanim.55.349. PMID:16880682.
11. Kanter, M., Altan, M.F., Donmez, S., Ocakci, A., and Kartal, M.E. 2007. The effects of quercetin on bone minerals, biomechanical behavior, and structure in streptozotocin induced diabetic rats. Cell Biochem. Funct. 25(6): 747-752. doi:10.1002/cbf.1397. PMID:17265531.
12. Kim, D.S., Takai, H., Arai, M., Araki, S., Mezawa, M., Kawai, Y., et al. 2007. Effects of quercetin and quercetin 3 glucuronide on the expression of bone sialoprotein gene. J. Cell Biochem. 101(3): 790-800. doi:10.1002/jcb.21233. PMID: 17243115.
13. Liu, R.H., Albrecht, J., and Werth, V.P. 2006. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch. Dermatol. 142(1): 37-41. doi:10.1001/archderm.142.1.37. PMID: 16415384.
14. Löfberg, E., Gutierrez, A., Wernerman, J., Anderstam, B., Mitch, W., Price, S., et al. 2002. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur. J. Clin. Invest. 32(5): 345-353. doi:10.1046/j.1365-2362.2002.00993.x. PMID:12027875.
15. Luckman, S.P., Hughes, D.E., Coxon, F.P., Russell, R.G.G., and Rogers, M.J. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13(4): 581-589. doi:10.1359/jbmr.1998.13.4.581. PMID:9556058.
16. Mazziotti, G., Angeli, A., Bilezikian, J.P., Canalis, E., and Giustina, A. 2006. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17(4): 144-149. doi:10.1016/j.tem.2006.03.009. PMID:16678739.
17. McDonough, A.K., Curtis, J.R., and Saag, K.G. 2008. The epidemiology of glucocorticoid-associated adverse events. Curr. Opin. Rheumatol. 20(2): 131-137. doi:10.1097/BOR.0b013e3282f51031. PMID:18349741.
18. Odvina, C.V., Zerwekh, J.E., Rao, D.S., Maalouf, N., Gottschalk, F.A., and Pak, C.Y.C. 2005. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90(3): 1294-1301. doi:10.1210/jc.2004-0952. PMID:15598694.
19. Olfert, E.D., Cross, B.M., McWilliam, A.A., and Care, C.C.o.A. 1993. Guide to the care and use of experimental animals. Vol. 1. Canadian Council on Animal Care, Ottawa, Ontario, Canada.
20. Prouillet, C., Maziere, J.C., Mazière, C., Wattel, A., Brazier, M., and Kamel, S. 2004. Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem. Pharmacol. 67(7): 1307-1313. doi:10.1016/j.bcp.2003.11.009. PMID:15013846.
21. Simpson, C.W., DiCara, L.V., and Wolf, G. 1974. Glucocorticoid anorexia in rats. Pharmacol. Biochem. Behav. 2(1): 19-25. doi:10.1016/0091-3057(74)90130-0. PMID:4828480.
22. Son, Y.O., Kook, S.H., Choi, K.C., Jang, Y.S., Choi, Y.S., Jeon, Y.M., et al. 2008. Quercetin accelerates TNF-_-induced apoptosis of MC3T3-E1 osteoblastic cells through caspase-dependent and JNK-mediated pathways. Eur. J. Pharmacol. 579(1-3): 26-33. doi:10.1016/j.ejphar.2007.10.003. PMID:17988664.
23. Tsuji, M., Yamamoto, H., Sato, T., Mizuha, Y., Kawai, Y., Taketani, Y., et al. 2009. Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice. J. Bone Miner. Metab. 27(6): 673-681. doi:10.1007/s00774-009-0088-0. PMID:19495926.
24. Wang, Y., Ohtsuka-Isoya, M., Shao, P., Sakamoto, S., and Shinoda, H. 2002. Effects of methylprednisolone on bone formation and resorption in rats. Jpn. J. Pharmacol. 90(3): 236-246. doi:10.1254/jjp.90.236. PMID:12499578.
25. Wattel, A., Kamel, S., Mentaverri, R., Lorget, F., Prouillet, C., Petit, J.P., et al. 2003. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem. Pharmacol. 65(1): 35-42. doi:10.1016/S0006-2952(02)01445-4. PMID:12473376.
26. Wattel, A., Kamel, S., Prouillet, C., Petit, J.P., Lorget, F., Offord, E., et al. 2004. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF B and AP 1. J. Cell. Biochem. 92(2): 285-295. doi:10.1002/jcb.20071.PMID:15108355.
27. Won Jahng, J., Kim, N.Y., Ryu, V., Yoo, S.B., Kim, B.T., Kang, D.W., et al. 2008. Dexamethasone reduces food intake, weight gain and the hypothalamic 5-HT concentration and increases plasma leptin in rats. Eur. J. Pharmacol. 581(1-2): 64-70. doi:10.1016/j.ejphar.2007.11.029. PMID:18164702.
28. Wong, R., and Rabie, A. 2008a. Effect of quercetin on preosteoblasts and bone defects. Open Orthop. J. 10(2): 27-32. doi:10.2174/1874325000802010027. PMID:19461927.
29. Wong, R., and Rabie, A. 2008b. Effect of quercetin on bone formation. J. Orthop. Res. 26(8): 1061-1066. doi:10.1002/jor.20638. PMID:18383168.
30. Woo, J.T., Nakagawa, H., Notoya, M., Yonezawa, T., Udagawa, N., Lee, I.S., et al. 2004. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol. Pharm. Bull. 27(4): 504-509. doi:10.1248/bpb.27.504. PMID:15056855.
31. Yamaguchi, M., Hamamoto, R., Uchiyama, S., and Ishiyama, K. 2007. Effects of flavonoid on calcium content in femoral tissue culture and parathyroid hormone-stimulated osteoclastogenesis in bone marrow culture in vitro. Mol. Cell. Biochem. 303(1): 83-88. doi:10.1007/s11010-007-9458-x. PMID: 17541507.
32. Yang, Y., Yang, Z., Wang, D., Xiao, X., and Li, P. 2006. Comparative study on effects of rutin and quercetin on metabolism in osteoblast cells. Zhong Yao Cai, 29(5): 467-470. PMID:16981462.
33. Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M.C., and Lane, N.E. 2008. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoid treated mice. Arthritis Rheum. 58(6): 1674-1686. doi:10.1002/art.23454. PMID:18512788.